Tobacco use continues to be a primary contributor to the global burden of disease, causing an estimated 12% of deaths worldwide among people aged 30 and […]
Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug […]